,:FAP-4-1BBL

Javier Sanchez1,2, Christina Claus3, Christine McIntyre4

  • 1Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.

Frontiers in pharmacology
|October 24, 2024
PubMed
概括

优化双特定抗体结合亲和力通过增加T细胞激活来增强癌症免疫疗法. 较高的亲和力减少了目标受体的需求,并扩大了纤维细胞激活蛋白α (FAP) 导向疗法的患者人群覆盖范围.

相关概念视频